Borchmann, Sven (2022). Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma. Hematol.-Am. Soc. Hematol. Educ. Program (1). S. 717 - 723. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Full text not available from this repository.

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma that has traditionally been consid-ered a sub group of Hodgkin lym phoma. However, mor phol ogy, sur face marker expres sion, genet ics, and clin i cal course are dif fer ent from clas sic Hodgkin lym phoma. While most patients expe ri ence indo lent dis ease with slow pro gres sion, some patients can also have more aggres sive dis ease. Nevertheless, out comes are excel lent, and excess mor tal ity due to NLPHL is at most very low. The treat ment of newly diag nosed NLPHL has his tor i cally mir rored that of clas sic Hodgkin lym phoma. However, evi dence for devi a tions from that approach has emerged over time and is discussed herein. Less evi dence is avail able for the opti mal man age ment of relapsed patients. So -called var i ant his tol ogy has recently emerged as a bio log i cal risk fac tor, pro vid ing at least a par tial expla na tion for the observed het ero ge ne ity of NLPHL. Considering var i ant his tol ogy together with other risk fac tors and care ful obser va tion of the clin i cal course of the dis ease in each patient can help to assess indi vid ual dis ease aggres sive ness. Also impor tant in this mostly indo lent dis ease are the pref-er ences of the patient and host fac tors, such as indi vid ual sus cep ti bil ity to spe cific treat ment side effects. Considering all this together can guide individualized treatment recommendations, which are paramount in this rare disease.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Borchmann, SvenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-657342
DOI: 10.1182/hematology.2022000364
Journal or Publication Title: Hematol.-Am. Soc. Hematol. Educ. Program
Number: 1
Page Range: S. 717 - 723
Date: 2022
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 1520-4383
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
LONG-TERM; PHASE-II; RITUXIMAB; THERAPY; TRANSFORMATION; IMPACT; ABVDMultiple languages
Education, Scientific Disciplines; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/65734

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item